Physician profile
Joseph E Abreu
NPI 1003996240
$1,816.43
in general payments reported to CMS, 2019-2025
14 companies · $16.03 in 2025
The $16.03 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $310 · 2020: $308 · 2021: $588 · 2022: $119 · 2023: $257 · 2024: $219 · 2025: $16.03.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $492.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $492.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $948.04 | 2019-2025 | Cardiomems, Jot Dx |
| E.R. Squibb & Sons, L.L.C. | $283.12 | 2021-2024 | Camzyos, Eliquis |
| Pfizer INC. | $230.94 | 2019-2023 | |
| Amgen INC. | $93.15 | 2019-2024 | Repatha |
| Sanofi-Aventis U.S. LLC | $45.81 | 2019 | |
| Janssen Pharmaceuticals, INC | $38.25 | 2020-2023 | Xarelto |
| Preventice Services, LLC | $34.23 | 2019-2020 | |
| Esperion Therapeutics, INC. | $27.02 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $22.21 | 2023 | Inpefa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.60 | 2021 | |
| Novartis Pharmaceuticals Corporation | $19.73 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $18.25 | 2024 | Farxiga |
| Bardy Diagnostics, INC. | $17.71 | 2020 | |
| United Therapeutics Corporation | $16.37 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Abreu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.